Navigation Links
Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference

THE WOODLANDS, Texas, Jan. 4, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Dr. Arthur T. Sands, president and chief executive officer, will present at the JPMorgan Healthcare Conference in San Francisco, California on Monday, January 10, 2011 at 10:30 a.m. Pacific Time.  Dr. Sands will provide an overview of Lexicon's latest clinical data and drug development objectives.

A live webcast of the presentation will be available through Lexicon's corporate website at An archived version of the presentation will be available for 30 days after the event.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
2. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
3. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
4. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
5. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
6. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
7. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
8. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
9. Lexicon to Present at BIO International Convention
10. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
11. Lexicon Announces Proposed $95 Million Common Stock Offering
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... GKhair & Tibolli team members and artists were excited ... on November 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto ... and top of the line fashion journalists. The San Juan Beauty Show carries immense ...
(Date:11/30/2015)... ... November 30, 2015 , ... Winscribe ... at the Radiological Society of North America (RSNA) 2015 conference. , Leading ... cutting-edge dictation and speech-enabled documentation software, announced their partnership today at RSNA ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announces the Unstoppable Swappables, a household invention that provides an economical and easy ... a year and is growing at 2.6%," says Scott Cooper, CEO and Creative ...
(Date:11/29/2015)... ... November 29, 2015 , ... ... Institute of Ultrasound in Medicine! , AIUM ultrasound practice accreditation is a ... or exceed nationally recognized standards in the performance and interpretation of diagnostic ...
(Date:11/29/2015)... Ca (PRWEB) , ... November 29, 2015 , ... Khanna ... American Board of Ophthalmology on November 25th 2015. Peer Certification by the ... field of his specialty. Certification in Ophthalmology is first obtained after the completion of ...
Breaking Medicine News(10 mins):